AnaptysBio, Inc. (NASDAQ:ANAB) reported $176.4 million of income from continuing operations for the six months ended June 30 in results released September 21. A $181.5 million income-tax benefit, primarily from releasing a deferred-tax valuation allowance, turned a $5.1 million pretax loss into that profit.
The tax adjustment reflects greater expected use of tax assets following the separation of First Tracks Biotherapeutics. Recognizing those future tax benefits does not produce an equivalent cash receipt. The investment question is when growing royalties will leave enough cash after contractual obligations and corporate expenses to support shareholder returns.
Bull Case
AnaptysBio, Inc. has an expanding commercial foundation. Second-quarter collaboration revenue increased to $27.5 million from $22.3 million, while Jemperli royalties grew 25%. Global sales of the cancer drug reached $331 million, up 26%.
The royalty structure offers further upside as sales expand. Rates rise across successive annual sales tiers, from 8% on the first $1 billion to 25% on sales above $2.5 billion. Higher sales can therefore generate proportionately faster royalty growth when additional revenue reaches higher tiers.
The more immediate milestone is the Sagard royalty-monetization arrangement. AnaptysBio, Inc. previously received upfront funding in exchange for future receipts. Management estimates approximately $299 million remains after accrued royalties and milestones and expects paydown in the second half of 2027.
Once the contractual payment threshold is satisfied, subsequent Jemperli royalties and milestones revert to AnaptysBio, Inc.. That would materially improve the cash available to cover overhead and fund potential distributions. The timing depends on commercial performance and actual payments.
Have a look at: BioMarin (BMRN) Secured 20% U.S. Royalties on Yuviwel. Is Monetizing a Rival Better than Blocking It?
Bear Case
The distinction between earned royalties and retained cash remains central. Sagard receives assigned payments until the agreement’s threshold is met. Revenue growth can strengthen the eventual cash-generation opportunity while providing limited immediate spending capacity.
The transition filing reported $1.4 million of operating cash used by continuing operations during the first half, improved from $11.4 million a year earlier. Another $19.7 million of royalty-liability principal repayments appeared in financing cash flows. Operating cash flow alone therefore does not capture all financing-related cash obligations.
Costs also matter. AnaptysBio, Inc. reported second-quarter general and administrative expenses of $16.0 million, compared with $4.0 million a year earlier. Separation-related legal work, the lawsuit involving its Jemperli collaboration, and noncash stock compensation contributed to the increase.
The lawsuit also puts contractual rights in focus. AnaptysBio, Inc. is seeking the return of Jemperli rights from Tesaro, with a judgment anticipated in Q4 2026 or Q1 2027. An adverse outcome could materially affect contractual rights and financial position, making litigation relevant to the projected royalty stream and shareholder returns as well as legal expenses.
Capital-return authorization is another distinction. No shares had been repurchased under the $100 million repurchase plan as of June 30. The authorization permits purchases; it does not establish a distribution schedule.
Hedge Fund Sentiment
The filings available so far reflect positions held before AnaptysBio, Inc. reported its second-quarter and transitional fiscal-year 2026 results. Insider Monkey’s database showed 34 hedge funds holding AnaptysBio, Inc. at the end of 2Q2026, up from 33 funds three months earlier.
Conclusion
AnaptysBio, Inc. offers a credible royalty-growth story, with potential cash-flow improvement when the Sagard arrangement ends. The tax-driven profit does little to establish the timing of shareholder returns. Actual royalty receipts, progress toward contractual paydown, the litigation outcome, recurring costs, and completed capital returns are the decisive measures.
READ NEXT: Pan American Silver (PAAS) Updates its Reserve Base. How Much Growth Reflects Better Mines? and Lennar (LEN) Cuts Delivery Forecast. Can Construction Savings Offset Heavy Incentives?
This article is originally published at Insider Monkey.
